Supernus Pharmaceuticals Skyrockets on FDA Approval

Supernus Pharmaceuticals

is trading significantly higher on the session after it announced the FDA approval for Trokendi XR. The Company also announced that the FDA denied the Citizen's Petition filed in 2011 by Upsher Smith Laboratories as it relates to its NDA on Trokendi XR. Jack Khattar, Chief Executive Officer, President and Director of Supernus stated, "We are pleased to announce that the FDA granted us tentative approval for Trokendi XR and that all of the scientific and procedural conditions for approval have been met. We will continue to work closely with the FDA to further understand the outstanding issue and move forward towards final approval." Supernus Pharmaceuticals is currently trading at $13.14, a gain of $7.43 or 130.12%.